Cell & bioscienceJan 12, 2026

GLP-1 drug and Akk11 bacteria together reduce fat and improve fatty liver disease in diabetic mice

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

Adding Akkermansia muciniphila Akk11 appeared to strengthen semaglutide's metabolic and liver benefits in diabetic mice.

Evidence

This preclinical db/db mouse study measured metabolic, liver and adipose histology, gut microbiota, transcriptomic, and inflammatory changes after semaglutide alone or combined with Akk11.

Caveat

The evidence is limited to a mouse model and does not establish whether this microbiota-guided combination improves MASLD outcomes in humans.

Simplified

AIMS/HYPOTHESIS: Metabolic dysfunction-associated steatotic liver disease () is a leading cause of chronic liver disease globally and is closely associated with type 2 diabetes (T2D) and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer partial therapeutic benefits in MASLD, but their efficacy is often limited in advanced insulin-resistant states, highlighting the need for adjunctive strategies to improve treatment responsiveness.

METHODS: We investigated the metabolic and mechanistic effects of combining semaglutide () with Akkermansia muciniphila 11 (Akk11) in db/db mice, a model of T2D-associated MASLD. Mice were treated with semaglutide alone or in combination with Akk11. Metabolic parameters, hepatic and adipose tissue morphology, gut microbiota composition, transcriptomic profiles, and inflammatory signaling were evaluated.

RESULTS: GLP-1RA monotherapy elicited only modest improvements in glycemia and hepatic lipid accumulation, with effects waning over time. However, Akk11 supplementation significantly enhanced semaglutide therapeutic effects, leading to reduced subcutaneous and visceral fat, improved liver histology, and decreased serum triglycerides. Mechanistically, combination treatment suppressed fatty acid synthesis, promoted mitochondrial function, and remodeled the gut microbiota. Notably, both GLP-1RA and AKK attenuated intestinal pyroptosis pathways, and the combination further suppressed pro-inflammatory markers in the liver and intestine.

CONCLUSIONS/INTERPRETATION: Our findings highlight a synergistic interaction between GLP-1RA and Akk11, likely mediated through microbiota remodeling and parallel improvements in lipid metabolism across intestinal, hepatic, and adipose compartments. This study supports the development of microbiota-guided strategies to enhance therapies for MASLD and other metabolic diseases.

Key numbers

17×

Fat Mass Reduction

Comparison of fat mass reduction in T2D mice receiving combined treatment vs. alone.

114 upregulated and 482 downregulated genes

Hepatic Steatosis Improvement

Differential gene expression analysis in liver tissues from mice treated with and Akk11.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Featured in

GLP-1 TherapiesIssue #20

GLP-1 drugs show promise for kidney transplant patients and Alzheimer's, but may increase eye problems

↗

GLP-1 drug and Akk11 bacteria together reduce fat and improve fatty liver disease in diabetic mice

Abstract

Key numbers

Full Text

Featured in

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

Featured in

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief